Correlates of Segmental Pulse Wave Velocity in Older Adults: The Atherosclerosis Risk in Communities (ARIC) Study by Meyer, Michelle L. et al.
114 American Journal of Hypertension 29(1) January 2016
Original article
Pulse wave velocity (PWV) is a valid and reliable measure of 
arterial stiffness that predicts cardiovascular disease (CVD) 
events and all-cause mortality in clinical and community-
based studies.1 Carotid-femoral PWV (cfPWV) is the ref-
erence standard measurement of central aortic stiffness,2,3 
although the use of brachial-ankle PWV (baPWV) is favored 
in research studies for practical reasons, especially in East 
Asian countries such as Japan. baPWV can be measured using 
an automated measurement technique and represents a com-
posite measure of central and peripheral arterial stiffness.4–6
While baPWV is correlated with cardiovascular risk fac-
tors7,8 and mortality,9,10 it is unclear how much of the reported 
associations correspond to the central or peripheral vascula-
ture. Few studies have documented that baPWV is correlated 
with cfPWV,4,5,11 and peripheral arterial stiffness measured 
by femoral-ankle PWV (faPWV);8 however, studies have 
shown conflicting associations between CVD risk factors and 
faPWV.6,12,13 Age, for example, an established risk factor for 
arterial stiffening, is not associated with peripheral stiffness,14,15 
but is associated with higher cfPWV.16 The reported association 
between age and baPWV is inconsistent,2,17 suggesting that risk 
factor associations with baPWV reflect its properties as a com-
posite measure of central and peripheral arterial segments.
Central arteries contain multiple layers of elastin, whereas 
peripheral arteries contain more smooth muscle cells. It is 
necessary, therefore, to characterize segment-specific PWV 
since arterial architecture and function vary considerably 
across the arterial tree, and arterial tissue remodeling associ-
ated with aging and vascular risk factors also varies across 
arterial territories.18–23
Few studies measure peripheral and central PWV, limit-
ing our knowledge of the degree to which risk factor asso-
ciations differ by central (cfPWV), peripheral (faPWV), and 
composite central and peripheral (baPWV) arterial stiffness. 
Our aim was to measure segment-specific arterial stiffness 
and evaluate its correlates in a well-characterized population 
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METHODS
We evaluated segment-specific PWV (cfPWV, baPWV, and femoral-ankle 
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in the community-based Atherosclerosis Risk in Communities (ARIC) 
Study using a standardized protocol and the OMRON VP-1000 Plus sys-
tem. We examined the distribution and multivariable-adjusted corre-
lates of PWV measures by race and sex.
RESULTS
Mean age ranged from 74 ± 5 to 76 ± 5 years across race–sex groups. In 
all race–sex groups, cfPWV correlated with baPWV but not with faPWV, 
and cfPWV and baPWV were higher with age, whereas faPWV was not. 
Heart rate and systolic blood pressure (SBP) were positively associated 
and weight was negatively associated with all PWV measures; how-
ever, the associations with age, glycated hemoglobin, triglycerides, 
and high-density lipoprotein (HDL) cholesterol varied by segment and 
race–sex group.
CONCLUSIONS
Our findings indicate that cfPWV and faPWV reflect distinct aspects of 
segment-specific vascular stiffness and their associated profile of car-
diovascular risk factors. Even among older adults, age is associated with 
higher cfPWV and baPWV, but not with faPWV. Understanding factors 
that ostensibly play a role in increasing arterial stiffness in different 
arterial territories can inform opportunities for cardiovascular disease 
(CVD) prevention and risk management.
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of older adult African American and Caucasian men and 
women from the Atherosclerosis Risk in Communities 
(ARIC) Study. Understanding these relationships would 
inform hypotheses regarding the pathophysiological impli-
cations of risk factors for vascular stiffness and the develop-
ment of CVD.
METHODS
Study population
The ARIC Study is a population-based, longitudinal study 
of 15,792 participants aged 45–64  years enrolled between 
1987 and 1989 in 4 US communities (Forsyth County, North 
Carolina; Jackson, Mississippi; Minneapolis, Minnesota; 
and Washington County, Maryland). Details of the baseline 
visit have been previously described.24 This analysis includes 
5,683 participants who attended visit 5 between 2011 and 
2013 and had PWV measured (6,538 total participants at 
visit 5; 65% response rate from 10,036 eligible participants). 
We excluded participants with missing information on 
PWV, body mass index (BMI) ≥40 kg/m2, major arrhyth-
mias (Minnesota code 8-1-3, 8-3-1, and 8-3-2), Minnesota 
code 8-1-2 with evidence of biased PWV waveforms, aor-
tic aneurysms, abdominal aorta ≥5 cm, history of aortic or 
peripheral revascularization or aortic graft, aortic stenosis, 
moderate or greater aortic regurgitation, and missing covar-
iates of interest (BMI, systolic blood pressure (SBP), heart 
rate, and smoking). Participants who self-identified as Asian 
and African American participants from Minnesota and 
Maryland sites were also excluded due to small numbers. 
After exclusions, the final analytic sample included 4,974 
participants. Participants provided written informed con-
sent, and the study was approved by the Institutional Review 
Boards at all field centers, coordinating center, and central 
labs and reading centers.
Participants were asked to bring all prescription and non-
prescription medications taken within 2 weeks, to not con-
sume food or drinks, and refrain from tobacco and vigorous 
physical activity after midnight prior to the clinic visit or 
for 8 hours prior to the visit. Examinees underwent a blood 
draw, B-mode scan of the abdominal aorta, standard 12-lead 
electrocardiogram, anthropometric measurements, and 
interviewer-administered questionnaires to obtain medical 
history and lifestyle information. Body weight was meas-
ured to the nearest 0.1 kg, and height was recorded to the 
nearest centimeter. Waist circumference was measured in 
duplicate using standardized reference points. Three seated 
blood pressure measurements were obtained after a 5-min-
ute rest using an oscillometric automated sphygmomanom-
eter (Omron HEM-907 XL, Omron, Kyoto, Japan), and the 
average of the last 2 measurements was used.
Hypertension was defined as SBP ≥140 mm Hg, diastolic 
blood pressure ≥90 mm Hg, or antihypertensive medica-
tion use. Diabetes was defined as fasting glucose ≥126 mg/
dl, non-fasting glucose ≥200 mg/dl, antidiabetic medica-
tion use, or self-reported diagnosis of diabetes. Prevalent 
coronary heart disease and stroke were defined by ARIC 
cohort surveillance through 30 August 2013. Prevalent heart 
failure was defined as physician reported heart failure or a 
hospitalization discharge with an ICD code 428.x in the first 
position prior to visit 5. Prevalent peripheral arterial disease 
was defined as an ankle-brachial index of <0.9. Standard 
resting 12-lead electrocardiograms were digitally acquired 
using a GE MAC 1200 electrocardiograph (GE, Milwaukee, 
WI) at 10 mm/mV calibration and a speed of 25 mm/s. 
Electrocardiograms were centrally processed using GE 
12-SL Marquette Version 2001 (GE) at the Epidemiological 
Cardiology Research Center at the Wake Forest School of 
Medicine.
Blood samples were obtained following a standardized 
venipuncture protocol and shipped weekly to ARIC central 
laboratories where assays for total cholesterol, high-density 
lipoprotein (HDL) cholesterol, triglycerides, and fasting glu-
cose were performed. Low-density lipoprotein was calcu-
lated using the Friedewald equation.25 Glycated hemoglobin 
(HbA1c) was measured in EDTA whole blood on the Tosoh 
HPLC Glycohemoglobin Analyzer (Tosoh Medics, San 
Francisco, CA) using an automated high performance liq-
uid chromatography method calibrated with standard values 
derived by the National Glycohemoglobin Standardization 
Program. The laboratory coefficient of variation was 1.9%.
Pulse wave velocity measures
Technicians measured cfPWV, baPWV, and faPWV fol-
lowing a standardized protocol with the automated wave-
form analyzer VP-1000 Plus (Omron, Kyoto, Japan)26 after 
participants were supine for 5–10 minutes. Carotid and fem-
oral arterial pressure waveforms were acquired for 30 sec-
onds by applanation tonometry sensors attached on the left 
common carotid artery (via neck collar) and left common 
femoral artery (via elastic tape around the hip). Bilateral bra-
chial and posterior-tibial arterial pressure waveforms were 
detected over 10 seconds by extremities cuffs connected to 
a plethysmographic and an oscillometric pressure sensor 
wrapped on both arms and ankles.
PWV was estimated as the distance between 2 arterial 
recording sites divided by transit time. Distance for cfPWV 
was measured with a segmometer for PWV measurements 
(Rosscraft, Surray, Canada), and calculated as the carotid to 
femoral distance minus the suprasternal notch to carotid dis-
tance. Distances for baPWV and faPWV were automatically 
calculated by the VP-1000 Plus using height-based formulas, 
as previously described.5 A  minimum of 2 measurements 
were taken per participant and the last 2 measurements were 
averaged. We included the right baPWV and faPWV meas-
urements for this analysis. Outliers defined as PWV values 3 
SDs above or below the mean were excluded from analyses.
Quality assurance for PWV included central training and 
recertification, quarterly equipment calibration, and ongo-
ing quality control reviews by one of the authors (H.T.) on a 
stratified random sample of 40 records per month with feed-
back provided to technicians. Approximately 78% of records 
were considered optimal quality, 17% were good quality, 
3% were acceptable, and none were poor or unacceptable. 
Repeat visits were conducted for a subset of participants 
at each field center approximately 4–8 weeks later (n = 79; 
mean age 75.7 years; 46 females). The intra-class correlation 
coefficients and 95% confidence intervals were 0.70 (0.59, 
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0.81) for cfPWV, 0.84 (0.78, 0.90) for baPWV, and 0.69 (0.59, 
0.79) for faPWV.27
Statistical methods
Participant characteristics were estimated as means and 
SDs, medians and 25th and 75th percentiles, or frequencies 
and percent, where appropriate. The distribution of cfPWV, 
baPWV, and faPWV was described using cumulative fre-
quency plots by race and sex. Differences between race and 
between sex within race groups were assessed using the 
Kolmogorov-Smirnov test. The relationship between PWV 
measurements and age were evaluated using Spearman 
correlations. We calculated means and the 95% confidence 
intervals for cfPWV, baPWV, and faPWV by 5-year age 
groups stratified by race and sex.
Associations between participant characteristics and risk 
factors with PWV were evaluated using multivariable linear 
regression. Independent variables included race, sex, age, 
center, current smoking, and prevalent coronary heart dis-
ease, heart failure, stroke, and peripheral arterial disease. 
Subsequent models included factors known to be associ-
ated with PWV, such as height, BMI, waist circumference, 
SBP, diastolic blood pressure, heart rate, total cholesterol, 
HDL, low-density lipoprotein, hypertension, diabetes, and 
medication use (β-blockers, α-blockers, calcium channel 
blockers, diuretics, angiotensin-converting enzyme inhibi-
tors, angiotensin II receptor blockers). We retained variables 
significantly associated with PWV (P < 0.1). Sets of similar 
factors were evaluated using the model adjusted R2 values, 
and those with the largest R2 were retained in the model. 
The sets evaluated include the following: (i) diabetes, fasting 
glucose, and HbA1c, (ii) SBP, mean arterial pressure, pulse 
pressure, and hypertension, and (iii) BMI, waist circumfer-
ence, height, and body weight. We report β coefficient esti-
mates, their precision, and the R2 values for the models. We 
evaluated nonlinear relationships between PWV and age 
and investigated first-order interactions between race and 
sex and with hypertension, diabetes, SBP, overweight (BMI 
≥ 25 kg/m2), and age. Results are stratified by race and sex 
because of significant race–sex interactions for all PWV 
measures. P-values were two-sided with statistical signifi-
cance of P < 0.05 (SAS, version 9.2, SAS Institute, Cary, NC).
RESULTS
A majority of participants were women (58.6%). The 
mean age ranged from 74.4 ± 4.9 to 75.8 ± 5.1 years, and the 
mean BMI ranged from 27.3 ± 4.7 to 29.8 ± 4.9 kg/m2 across 
race–sex groups (Table  1). The proportion of participants 
who reported current smoking ranged from 6% to 8%, and 
Caucasians had higher educational attainment compared 
with their African American counterparts. The prevalence of 
diabetes ranged from 24% among Caucasian women to 43% 
among African American men. The prevalence of hyper-
tension ranged from 69% among Caucasian women to 89% 
among African American women.
The distribution of PWV varied across race–sex groups. 
cfPWV was higher among African Americans compared 
with Caucasians and among Caucasian men compared with 
Caucasian women, as shown by the cumulative distribution 
curves (P < 0.001 for race, P = 0.001 for sex within Caucasians, 
P = 0.07 for sex within African Americans; Supplementary 
Figure 1). The cumulative distribution curves of baPWV did 
not vary significantly by race–sex group (P = 0.11 for race, 
P = 0.41 for sex within Caucasians, P = 0.19 for sex within 
African Americans; Supplementary Figure  2). faPWV was 
higher among Caucasians than African Americans, but 
no difference was seen by sex (P < 0.001 for race, P = 0.39 
for sex within Caucasians, P = 0.91 for sex within African 
Americans; Supplementary Figure 3).
In all race–sex groups, mean cfPWV and baPWV was 
higher across 5-year age groups from <70 to 85+ years 
(Figures 1 and 2). faPWV did not differ across age groups 
(Figure 3). In all race–sex groups, age was positively corre-
lated with cfPWV and baPWV (Spearman correlation range: 
0.17–0.30), but not with faPWV (Spearman correlation 
range: −0.04 to 0.04; Table  2). cfPWV was positively cor-
related with baPWV in all race–sex groups (Spearman cor-
relation range: 0.40–0.56), and only faPWV correlated with 
baPWV in all race–sex groups (Spearman correlation range: 
0.58–0.70; Table 2).
A common set of covariates were significantly related to 
PWV segments in the stepwise regression analyses (Table 3). 
Among sets of similar factors, those retained in the model 
according to R2 values included HbA1c, SBP, height, and 
body weight. Age was positively associated with cfPWV and 
baPWV, whereas age had a weak negative association with 
faPWV among African American women (Table 3). Heart 
rate and SBP were positively associated and body weight was 
negatively associated with all PWV segments.
Associations between height, HbA1c, triglycerides, and 
HDL with PWV differed across PWV segments and race–
sex groups (Table 3). Height was positively associated with 
cfPWV but negatively associated with faPWV. HbA1c was 
positively associated with cfPWV and baPWV, but not with 
faPWV. Triglycerides were positively associated with all 
PWV measures among Caucasian men and with cfPWV 
among African American women. HDL was negatively asso-
ciated with cfPWV and baPWV among Caucasian women.
DISCUSSION
This study is the first to investigate simultaneously char-
acteristics associated with central, peripheral, and com-
posite measures of arterial stiffness among a large, biracial 
population of older adults. Our findings show cfPWV and 
baPWV were higher across 5-year age groups from <70 
to 85+ years, whereas faPWV did not differ across age 
groups. Additionally, cfPWV and baPWV were moder-
ately correlated measures of arterial stiffness, and a com-
mon set of factors were associated with PWV segments 
in varying degrees. These factors included age, heart rate, 
SBP, height, body weight, HbA1c, triglycerides, and HDL. 
Segment-specific associations were observed with age, 
height, HbA1c, triglycerides, and HDL. Therefore, our data 
suggest that factors associated with arterial stiffness vary 
across arterial territories.
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Table 1. Descriptive characteristics of ARIC visit 5 participants with PWV by race and sex
  Caucasian African American
  Men n = 1,694 Women n = 2,208 Men n = 363 Women n = 709
 
Mean ± SD or median 
(25th, 75th percentile)
Mean ± SD or median (25th, 
75th percentile)
Mean ± SD or median (25th, 
75th percentile)
Mean ± SD or median 
(25th, 75th percentile)
Age (years) 75.8 ± 5.1 75.3 ± 5.0 74.4 ± 4.9 74.5 ± 5.0
Field center, n (%)        
 Forsyth Co., NC 427 (25.2) 540 (24.5) 25 (6.9) 40 (5.6)
 Jackson, MS 0 0 338 (93.1) 669 (94.4)
 Minneapolis, MN 691 (40.8) 880 (39.9) 0 0
 Washington Co., MD 576 (34.0) 788 (35.7) 0 0
Education, n (%)        
 <High school 146 (8.6) 199 (9.0) 108 (29.8) 186 (26.3)
 High school 498 (29.5) 932 (42.2) 63 (17.4) 167 (23.6)
 >High school 1,045 (61.9) 1,076 (48.8) 192 (52.9) 355 (50.1)
Current smoker, n (%) 94 (5.6) 123 (5.6) 29 (8.0) 44 (6.2)
Height (cm) 173.9 ± 6.6 159.3 ± 6.0 174.6 ± 6.8 161.4 ± 6.0
Weight (kg) 85.3 ± 13.8 69.2 ± 12.9 85.7 ± 14.8 77.8 ± 14.0
BMI (kg/m2) 28.2 ± 4.0 27.3 ± 4.7 28.1 ± 4.5 29.8 ± 4.9
Waist circumference (cm) 104.1 ± 10.6 97.1 ± 13.0 100.0 ± 11.5 96.7 ± 12.5
SBP (mm Hg) 127.9 ± 16.5 129.9 ± 17.8 131.8 ± 17.8 135.0 ± 18.4
DBP (mm Hg) 65.8 ± 10.4 65.3 ± 10.2 70.4 ± 10.8 69.7 ± 10.1
Pulse pressure (mm Hg) 62.0 ± 13.1 64.6 ± 14.7 61.4 ± 13.6 65.3 ± 15.3
Mean arterial pressure (mm Hg) 86.5 ± 11.1 86.9 ± 11.3 90.9 ± 11.9 91.5 ± 11.3
Heart rate (bpm) 59.7 ± 9.7 62.8 ± 9.5 64.3 ± 10.7 63.7 ± 10.7
Hypertension, n (%) 1,155 (69.2) 1,505 (68.5) 294 (81.2) 630 (89.2)
HbA1c (%) 5.7 (5.4, 6.1) 5.7 (5.4, 5.9) 6.0 (5.6, 6.5) 6.0 (5.6, 6.4)
Fasting glucose (mmol/l) 6.0 (5.6, 6.8) 5.8 (5.3, 6.4) 5.9 (5.4, 6.8) 5.8 (5.3, 6.7)
Diabetes, n (%) 537 (31.9) 525 (24.0) 154 (43.0) 276 (39.3)
LDL (mmol/l) 2.4 (1.9, 3.0) 2.8 (2.2, 3.4) 2.5 (2.1, 3.2) 2.8 (2.3, 3.5)
HDL (mmol/l) 1.1 (1.0, 1.3) 1.4 (1.2, 1.7) 1.2 (1.0, 1.4) 1.4 (1.2, 1.7)
Triglycerides (mmol/l) 1.3 (0.9, 1.8) 1.3 (1.0, 1.8) 1.0 (0.8, 1.4) 1.1 (0.9, 1.4)
Prevalent coronary heart disease, n (%) 401 (24.0) 166 (7.7) 44 (12.3) 55 (7.9)
Prevalent heart failure, n (%) 72 (4.3) 61 (2.8) 24 (6.6) 29 (4.1)
Prevalent stroke, n (%) 52 (3.1) 44 (2.0) 21 (5.8) 31 (4.4)
Prevalent peripheral arterial disease (ABI 
<0.9), n (%)
36 (2.2) 29 (1.3) 23 (6.5) 40 (5.7)
Medication use, n (%)        
 β-Blocker 532 (32.0) 637 (29.2) 81 (23.1) 155 (22.2)
 α-Blocker 59 (3.5) 49 (2.2) 17 (4.8) 43 (6.2)
 Diuretic 505 (30.3) 792 (36.3) 185 (52.7) 441 (63.1)
 Angiotensin-converting enzyme 
inhibitor
585 (35.1) 529 (24.2) 152 (43.3) 233 (33.3)
 Angiotensin receptor blocker 221 (13.3) 345 (15.8) 64 (18.2) 185 (26.5)
 Calcium channel blocker 345 (20.7) 431 (19.7) 134 (38.2) 302 (43.2)
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Figure 1. Mean carotid-femoral pulse wave velocity (cfPWV) by age group, race, and sex with 95% confidence intervals (CIs).
Figure 2. Mean brachial-ankle pulse wave velocity (baPWV) by age group, race, and sex with 95% confidence intervals (CIs).
  Caucasian African American
  Men n = 1,694 Women n = 2,208 Men n = 363 Women n = 709
 
Mean ± SD or median 
(25th, 75th percentile)
Mean ± SD or median (25th, 
75th percentile)
Mean ± SD or median (25th, 
75th percentile)
Mean ± SD or median 
(25th, 75th percentile)
Pulse wave velocity        
 cfPWV (cm/s) 1,162.8 ± 296.9 1,120.7 ± 282.3 1,247.3 ± 343.7 1,222.1 ± 331.5
 baPWV (cm/s) 1,742.1 ± 311.5 1,735.5 ± 316.3 1,709.4 ± 341.8 1,724.3 ± 304.1
 faPWV (cm/s) 1,106.1 ± 1788.8 1,114.3 ± 178.0 1,049.0 ± 187.2 1,051.8 ± 176.0
Abbreviations: ABI, ankle-brachial index; baPWV, brachial-ankle pulse wave velocity; BMI, body mass index; Co., county; cfPWV, carotid-
femoral pulse wave velocity; DBP, diastolic blood pressure; faPWV, femoral-ankle pulse wave velocity; HbA1c, glycated hemoglobin; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein; MD, Maryland; MN, Minnesota; MS, Mississippi; NC, North Carolina; PWV, pulse wave 
velocity; SBP, systolic blood pressure.
Table 1. Continued
American Journal of Hypertension 29(1) January 2016 119
Correlates of Pulse Wave Velocity
William Osler’s axiom that “man is as old as his arteries” 
typifies the widespread use of arterial stiffness as a biological 
marker of aging processes.5,17 In this study of community-
dwelling older adults, age was positively associated with 
cfPWV and baPWV, which was observed across all race–sex 
groups. In contrast, our data show no association between 
age and faPWV, with the exception of a small inverse asso-
ciation among African American women. The association 
between faPWV and age is inconsistent, with studies show-
ing no association between faPWV and age28 or weaker posi-
tive associations compared with central measures of arterial 
stiffness.13,29 These observations are consistent with the 
expectation that the muscular peripheral vasculature is less 
affected by age-related vascular changes.14,15
Consistent with prior studies, baPWV was significantly 
correlated with cfPWV,4–6 as would be expected since the 
2 measures are non-orthogonal. Also as expected, baPWV 
was associated with faPWV, although there was no statis-
tically significant correlation between cfPWV and faPWV. 
This is in contrast with the study by Choo et al. that showed 
all segments were significantly correlated with each other 
among a multiracial population of male adults, includ-
ing cfPWV and faPWV.6 Our results confirm prior studies 
showing that baPWV largely reflects stiffness of the central 
arteries,4,5 although peripheral arterial stiffness contributes 
to a substantial component of baPWV.
This study showed that heart rate, SBP, and weight were 
major correlates with all PWV segments. Heart rate and 
SBP have been consistently associated with cfPWV16,30 
and baPWV,6,8 and there is evidence of an association with 
faPWV.6 Weight was negatively associated will all PWV 
segments in this analysis. Similar to this study, Choo et al. 
showed that BMI negatively correlated to faPWV, but posi-
tively with other PWV segments.6 Obesity is associated with 
higher cardiac output and lower peripheral vascular resist-
ance31–33 that could contribute to a lower PWV.
The association between metabolic risk factors, such as 
HbA1c, triglycerides, and HDL with PWV varied across 
race–sex groups. Although racial differences in arterial 
hemodynamics have not been well studied, sex differences 
Figure 3. Mean femoral-ankle pulse wave velocity (faPWV) by age group, race, and sex with 95% confidence intervals (CIs).
Table 2. Spearman correlations with PWV by race and sex, values are correlation coefficient and P-value
  Caucasian African American
  Men (n = 1,464–1,660) Women (n = 1,973–2,023) Men (n = 334–359) Women (n = 657–693)
  cfPWV baPWV faPWV cfPWV baPWV faPWV cfPWV baPWV faPWV cfPWV baPWV faPWV
Age 0.23 0.27 0.04 0.3 0.29 0.04 0.25 0.17 −0.04 0.22 0.25 −0.01
  <0.0001 <0.0001 0.11 <0.0001 <0.0001 0.07 <0.0001 0.001 0.47 <0.0001 <0.0001 0.78
cfPWV   0.52 0.02   0.56 0.02   0.4 −0.05   0.41 −0.06
    <0.0001 0.41   <0.0001 0.46   <0.0001 0.39   <0.0001 0.12
baPWV     0.61     0.58     0.7     0.6
      <0.0001     <0.0001     <0.0001     <0.0001
Abbreviations: baPWV, brachial-ankle pulse wave velocity; cfPWV, carotid-femoral pulse wave velocity; faPWV, femoral-ankle pulse wave 
velocity; n, number.
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have been investigated. Brachial artery diameter increases 
with age in both men and women, but to a greater extent in 
women.15 Additionally, there is also evidence that the central 
waveform differs by sex.34 These observations suggest that 
the differential structural and functional properties of the 
vasculature that could affect PWV, such as adaptive remod-
eling, arterial wave reflection, and smaller arterial diameters 
and dimensions35,36 may explain the differential associations 
across race–sex groups.
Central arterial stiffness had a stronger association with 
HbA1c compared to other markers of glucose metabolism. 
Similar to these results, a previous study in 5,098 adults 
reported that cfPWV had a stronger association with HbA1c 
than with fasting glucose or glucose post 2-hour oral glu-
cose tolerant test.37 An association between HbA1c was also 
reported in hemodialysis patients with and without diabe-
tes.38 Since HbA1c serves as a marker of long-term glucose 
exposure, the observed association may index the formation 
of advanced glycation endproducts and cross-linking in col-
lagen molecules39 leading to arterial stiffening.
We observed an association between HDL and cfPWV and 
baPWV among Caucasian women. Similarly, HDL was not 
associated with cfPWV, baPWV, or faPWV among a popula-
tion of American, Japanese, and Korean men.40 Associations, 
however, were seen with lipoprotein subclasses and baPWV 
and faPWV. This suggests that an evaluation of lipoprotein 
Table 3. ARIC visit 5 multivariable linear regression associations with PWV by race and sex
Caucasian men Caucasian women African American men African American women
Covariate β (95% CI) β (95% CI) β (95% CI) β (95% CI)
cfPWV n = 1,425, R2 = 0.23 n = 1,903, R2 = 0.25 n = 315, R2 = 0.24 n = 633, R2 = 0.25
Age (years) 12.4 (9.5, 15.3)§ 12.7 (10.3, 15.0)§ 14.9 (7.9, 22.0)§ 11.5 (6.5, 16.4)§
Heart rate (bpm) 6.8 (5.3, 8.3)§ 6.8 (5.6, 8.1)§ 9.9 (6.5, 13.2)§ 6.5 (4.3, 8.7)§
SBP (mm Hg) 4.9 (4.0, 5.7)§ 4.7 (4.0, 5.3)§ 5.5 (3.3, 7.7)§ 5.2 (4.0, 6.5)§
Height (cm) 3.9 (1.5, 6.4)† 5.8 (3.7, 7.8)§ 6.1 (0.4, 11.9)* 4.9 (0.7, 9.1)*
Weight (kg) −1.4 (−2.8, −0.1)* −2.5 (−3.5, −1.4)§ −3.0 (−5.9, −0.2)* −3.6 (−5.6, −1.6)‡
HbA1c (%) 52.8 (33.9, 71.6)§ 41.2 (23.9, 58.5)§ 34.8 (4.5, 65.2)* 30.7 (3.9, 57.5)*
Triglycerides (mmol/l) 24.7 (5.2, 44.3)* 15.7 (−1.1, 32.5) −12.5 (−68.4, 43.5) 58.6 (5.1, 112.1)*
HDL (mmol/l) −24.4 (−76.5, 27.6) −38.0 (−73.3, −2.7)* 44.0 (−90.4, 178.4) −67.3 (−137.2, 2.6)
baPWV n = 1,595, R2 = 0.28 n = 2,057, R2 = 0.32 n = 332, R2 = 0.32 n = 661, R2 = 0.31
Age (years) 12.8 (10.0, 15.5)§ 11.9 (9.5, 14.3)§ 8.4 (2.0, 14.7)† 11.4 (7.1, 15.6)§
Heart rate (bpm) 5.7 (4.3, 7.1)§ 6.4 (5.1, 7.6)§ 5.4 (2.4, 8.4)† 4.7 (2.9, 6.6)§
SBP (mm Hg) 6.8 (6.0, 7.6)§ 6.5 (5.8, 7.1)§ 7.7 (5.8, 9.6)§ 5.3 (4.2, 6.4)§
Height (cm) −1.7 (−4.0, 0.7) 0.5 (−1.6, 2.7) −3.5 (−8.6, 1.6) 0.9 (−2.8, 4.5)
Weight (kg) −2.9 (−4.1, −1.7)§ −5.2 (−6.3, −4.2)§ −4.4 (−6.9, −1.9)‡ −6.6 (−8.3, −5.0)§
HbA1c (%) 27.7 (10.1, 45.3)† 16.8 (−0.8, 34.5) 16.0 (−11.2, 43.2) 38.7 (16.4, 60.9)‡
Triglycerides (mmol/l) 20.0 (1.2, 38.9)* 16.9 (−0.2, 33.9) 25.0 (−25.7, 75.8) 54.9 (11.4, 98.4)*
HDL (mmol/l) −17.7 (−67.9, 32.5) −51.7 (−87.6, −15.7)† −64.0 (−183.6, 55.5) −28.7 (−88.6, 31.2)
faPWV n = 1,418, R2 = 0.19 n = 1,887, R2 = 0.17 n = 314, R2 = 0.22 n = 634, R2 = 0.18
Age (years) −0.01 (−1.8, 1.8) −1.5 (−3.1, −0.03) −2.7 (−6.6, 1.1) −3.0 (−5.7, −0.2)*
Heart rate (bpm) 1.6 (0.7, 2.5)‡ 2.2 (1.4, 3.0)§ 1.5 (−0.3, 3.3) 1.6 (0.4, 2.8)†
SBP (mm Hg) 2.5 (2.0, 3.0)§ 2.0 (1.6, 2.4)§ 2.4 (1.2, 3.5)§ 1.4 (0.7, 2.1)§
Height (cm) −2.3 (−3.8, −0.7)† −1.6 (−3.0, −0.3)* −4.8 (−8.0, −1.6)† −3.2 (−5.5, −0.9)†
Weight (kg) −2.3 (−3.1, −1.4)§ −3.2 (−3.9, −2.5)§ −1.4 (−3.0, 0.1) −2.6 (−3.7, −1.6)§
HbA1c (%) −0.9 (−10.6, 12.4) −0.5 (−12.0, 10.9) −0.02 (−16.8, 16.8) 8.4 (−6.0, 22.7)
Triglycerides (mmol/l) 15.3 (3.5, 27.2)* 3.0 (−8.1, 14.1) 25.5 (−5.3, 56.3) 17.2 (−12.3, 46.8)
HDL (mmol/l) −12.6 (−45.2, 20.0) 10.1 (−13.4, 33.5) 6.6 (−65.1, 78.3) 13.6 (−25.2, 52.4)
Values are βs, 95% confidence intervals (95% CI), and model adjusted R2; models were additionally adjusted for center, current smoking, 
prevalent comorbidities (coronary heart disease, heart failure, stroke, peripheral arterial disease), β-blockers, α-blockers, calcium channel 
blockers, and diuretics.
Abbreviations: baPWV, brachial-ankle pulse wave velocity; cfPWV, carotid-femoral pulse wave velocity; faPWV, femoral-ankle pulse wave 
velocity; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; PWV, pulse wave velocity; SBP, systolic blood pressure.
*P < 0.05, †P ≤ 0.01, ‡P ≤ 0.001, §P ≤ 0.0001.
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subclasses might elucidate the relationship of lipoproteins and 
arterial stiffness.
Limitations of our study should be noted. The cross-sec-
tional design precludes the assessment of causality in the 
observed associations. On occasion, some PWV measure-
ments were not collected due to technical issues, participant 
factors, and scheduling conflicts. Since the African American 
members of the ARIC cohort predominantly reside in 
Jackson, MS, the observed associations may not generalize 
to African Americans as a demographic group. Similarly, our 
population consisted of older adults, limiting the generaliz-
ability of our findings to younger populations. Distance for 
cfPWV was measured over the body and may not reflect the 
actual length of the aorta, and the degree of measurement 
error could also be affected by the tortuosity of the aorta. 
Height-based formulas to calculate baPWV and faPWV were 
validated in a Japanese population and may not be applicable 
to other race or ethnic groups, which would limit general-
izability of this study and technology. The potential bias in 
length calculations limits the ability to compare baPWV and 
faPWV across ethnic groups, although it would have a small 
effect on our conclusions since risk factor associations with 
PWV measures were race and sex stratified.
This study extends the observation that cfPWV and 
baPWV are correlated and non-orthogonal measures of 
arterial stiffness, and shows that faPWV has dissimilar asso-
ciations with risk factors. Despite the correlated nature of 
cfPWV and baPWV, the latter spans a more heterogeneous 
arterial tree and subsumes greater heterogeneity. It is thus 
likely that associations of risk factors with baPWV reflect a 
composite of the different associations exhibited by some of 
these factors with cfPWV and with faPWV, while other fac-
tors were related comparably to cfPWV and baPWV.
Our results expand on previously reported differences in the 
profile of factors associated with central (cf) and peripheral 
(fa) PWV and highlight the benefits of segment-specific meas-
ures of PWV. The widely used baPWV predominantly reflects 
not only the central arterial stiffness but also the peripheral 
stiffness. Segment-specific measures open the opportunity 
to understand factors that ostensibly play a role in increasing 
arterial stiffness in different arterial territories and can inform 
opportunities for CVD prevention and risk management.
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